Abstract

The Argan tree (Argania spinosa. L) is an evergreen tree endemic of southwestern Morocco. For centuries, various formulations have been used to treat several illnesses including diabetes. However, scientific results supporting these actions are needed. Hence, Argan fruit products (i.e., cake byproducts (saponins extract) and hand pressed Argan oil) were tested for their in-vitro anti-hyperglycemic activity, using α-glucosidase and α-amylase assays. The in-vivo anti-hyperglycemic activity was evaluated in a model of alloxan-induced diabetic mice. The diabetic animals were orally administered 100 mg/kg body weight of aqueous saponins cake extract and 3 mL/kg of Argan oil, respectively, to evaluate the anti-hyperglycemic effect. The blood glucose concentration and body weight of the experimental animals were monitored for 30 days. The chemical properties and composition of the Argan oil were assessed including acidity, peroxides, K232, K270, fatty acids, sterols, tocopherols, total polyphenols, and phenolic compounds. The saponins cake extract produced a significant reduction in blood glucose concentration in diabetic mice, which was better than the Argan oil. This decrease was equivalent to that detected in mice treated with metformin after 2–4 weeks. Moreover, the saponins cake extract showed a strong inhibitory action on α-amylase and α-glucosidase, which is also higher than that of Argan oil.

Highlights

  • IntroductionType 2 diabetes mellitus (T2DM) and hypertension are the most shared comorbidities in coronavirus-infected patients [1]

  • The oil is rich in mono-unsaturated fatty acids (MUFA, 45%), which are mainly composed of oleic acid (C18:1, 31%) and gadoleic acid (C20:1, 0.19%)

  • The regular consumption of Argan oil could protect the human body from cancer and heart diseases [46]

Read more

Summary

Introduction

Type 2 diabetes mellitus (T2DM) and hypertension are the most shared comorbidities in coronavirus-infected patients [1]. In the current COVID-19 pandemic context and according to some papers [1,2], including those from the Centers for Disease Control and Prevention (CDC), patients with type 2 diabetes mellitus and the metabolic syndrome could suffer with an up to ten-times higher risk of dying when they contract COVID-19 [3]. T2DM is the most common endocrine disease with indirect relation to several other disorders. It is expected that more than 300 million persons worldwide will suffer from T2DM in 2025 [4]. T2DM is caused by an irregularity of the carbohydrate metabolism, which is directly connected to down insulin levels in blood [5,6]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call